Get the Stockscreener App
0.905
0.11%
-0.001
After Hours:
.86
-0.045
-4.97%
Xilio Therapeutics Inc stock is traded at $0.905, with a volume of 1.02M.
It is down -0.11% in the last 24 hours and up +30.78% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.906
Open:
$0.8891
24h Volume:
1.02M
Relative Volume:
0.28
Market Cap:
$45.31M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.3057
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-3.64%
1M Performance:
+30.78%
6M Performance:
+22.13%
1Y Performance:
+25.62%
1-Day Range:
$0.81
$0.9799
1-Week Range:
$0.81
$1.03
52-Week Range:
$0.58
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.905 | 45.31M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online
Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks
AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance
Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise
AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace
Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn
AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business
AbbVie, Xilio Hook up - Baystreet.ca
AbbVie expands oncology R&D with Xilio deal - The Pharma Letter
Xilio Therapeutics, Intel, Lithia Motors - TradingView
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal -February 12, 2025 at 08:42 am EST - Marketscreener.com
Abbvie and Xilio Therapeutics, Inc. Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Marketscreener.com
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech
Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion - TipRanks
Xilio shares soar on AbbVie collaboration deal By Investing.com - Investing.com Nigeria
AbbVie and Xilio Therapeutics announce collaboration - TipRanks
Abbvie And Xilio Therapeutics Announce Collaboration -February 12, 2025 at 07:51 am EST - Marketscreener.com
AbbVie and Xilio partner for tumor-activated therapies - Investing.com
Xilio Therapeutics Announces Collaboration with AbbVie to Advance Novel Tumor-Activated Immunotherapies with $52 Million Upfront Payment - Nasdaq
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewswire
Major Biotech Partnership: Xilio Secures $52M AbbVie Deal with Massive $2.1B Milestone Potential - StockTitan
Major Cancer Breakthrough: AbbVie Invests $52M in Xilio's Revolutionary Tumor-Fighting Technology - StockTitan
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - PR Newswire
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034 - GlobeNewswire Inc.
Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):